Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seroquel Sales Aid Cited By FDA For Minimizing Diabetes Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca’s material “undermines” class hyperglycemia and diabetes warnings from the atypical antipsychotic’s label, FDA says.

You may also be interested in...



Antipsychotic Marketing Investigation Broadens

Pfizer and Lilly join AstraZenenca under California attorney general’s microscope for marketing practices related to antipsychotics.

Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims

Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.

Lilly Zyprexa "Dear Doctor" Letter Warns Of Diabetes Risk

The letter notes that FDA has requested an atypical antipsychotics class warning describing the increased risk of hyperglycemia and diabetes.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel